ISSN Print: 2664-6595
ISSN Online: 2664-6609
IJHR 2023; 5(1): 10-13
www.hepatologyjournal.in
Received: 25-12-2022
Accepted: 30-01-2023

Dr. Katerina Dvorak
Department of Infectious Diseases, Charles University, Prague, Czech Republic

Dr. Tomas Havel
Department of Infectious Diseases, Charles University, Prague, Czech Republic

Corresponding Author:
Dr. Katerina Dvorak
Department of Infectious Diseases, Charles University, Prague, Czech Republic

Hepatic Cirrhosis in Chronic Hepatitis B and C Patients: A comparative study

Dr. Katerina Dvorak and Dr. Tomas Havel

DOI: https://doi.org/10.33545/26646595.2023.v5.i1a.17

Abstract
Chronic Hepatitis B (HBV) and hepatitis C (HCV) infections are leading causes of liver cirrhosis worldwide. This comparative study aims to evaluate the clinical progression, risk factors, and outcomes of hepatic cirrhosis in patients with chronic HBV and HCV infections. Data from 500 patients, equally divided between HBV and HCV cases, were analyzed for fibrosis staging, complications, and long-term survival outcomes. The study identifies key differences in disease progression, cirrhosis onset, and the efficacy of antiviral therapies. Findings suggest that while both infections lead to cirrhosis, the pathways and outcomes vary significantly between the two groups, with distinct implications for management and treatment strategies.

Keywords: Hepatic Cirrhosis, Chronic Hepatitis B and C Patients, treatment strategies, complications

Introduction
Hepatic cirrhosis is the end stage of chronic liver disease and is characterized by the replacement of normal liver tissue with scar tissue, leading to impaired liver function. The primary etiologies of cirrhosis are chronic viral infections, notably hepatitis B virus (HBV) and hepatitis C virus (HCV). Together, these viral infections are responsible for a significant portion of cirrhosis cases globally, accounting for millions of deaths each year due to cirrhosis-related complications such as liver failure, portal hypertension, and hepatocellular carcinoma (HCC). According to the World Health Organization (WHO), an estimated 296 million people worldwide are chronically infected with HBV, while approximately 58 million people have chronic HCV infection. While both HBV and HCV lead to cirrhosis, the mechanisms by which cirrhosis develops and progresses differ between the two infections. HBV-related cirrhosis is often associated with ongoing viral replication and immune-mediated liver damage, even in the absence of significant liver inflammation. In contrast, HCV-related cirrhosis is primarily driven by persistent liver inflammation and oxidative stress caused by viral replication. The progression to cirrhosis in HCV patients tends to be more closely linked to the duration of infection and comorbid factors such as alcohol use and metabolic syndrome. Antiviral therapies have improved the prognosis for patients with both HBV and HCV infections, but significant differences remain in treatment responses and outcomes. In chronic HBV infection, nucleos(t)ide analogues suppress viral replication, but complete eradication of the virus is rare. For chronic HCV infection, direct-acting antivirals (DAAs) can achieve sustained virologic response (SVR) in the majority of patients, effectively curing the infection and preventing cirrhosis progression.
This study aims to compare the clinical progression, cirrhosis onset, complications, and survival outcomes in patients with HBV- and HCV-related cirrhosis. By understanding the differences in cirrhosis development between these two chronic infections, we can optimize treatment strategies and improve patient management.

Objective of the study
The objective of the study is to compare the progression, complications, and outcomes of hepatic cirrhosis in patients with chronic hepatitis B and C infections.

Methodology
This retrospective study was conducted using medical records from 500 patients with chronic hepatitis B or C who developed hepatic cirrhosis.

The cohort included 250 patients with HBV-related cirrhosis and 250 with HCV-related cirrhosis. Patients were diagnosed based on liver biopsy results, imaging studies (ultrasound and elastography), and clinical presentation.

The key variables analyzed were the stage of liver fibrosis, cirrhosis onset (measured in years from diagnosis of HBV or HCV to cirrhosis), complications such as portal hypertension, ascites, and variceal bleeding, and overall survival. Patients were followed for a median period of 10 years. The study also considered the impact of antiviral therapy, including nucleos(t)ide analogues for HBV and DAAs for HCV, on cirrhosis progression and survival outcomes. Statistical analysis was performed using Kaplan-Meier survival curves to compare long-term outcomes between HBV and HCV patients. Logistic regression models were used to identify factors associated with rapid cirrhosis progression and to assess the efficacy of antiviral treatments.

Results

Table 1: Average Time to Cirrhosis Onset

Infection Type	Average Time to Cirrhosis (Years)	Percentage Developing Cirrhosis in First 15 Years
Hepatitis B (HBV)	20	60%
Hepatitis C (HCV)	25	40%

The average time from diagnosis of HBV infection to cirrhosis onset was 20 years, compared to 25 years for HCV patients. A higher proportion of HBV patients (60%) developed cirrhosis within the first 15 years of infection, whereas HCV-related cirrhosis typically developed over a longer period. Patients with HCV who also had risk factors such as alcohol use or metabolic syndrome showed significantly faster progression to cirrhosis.

Table 2: Complications of Cirrhosis in HBV and HCV Patients

Complication	HBV-Related Cirrhosis (%)	HCV-Related Cirrhosis (%)
Portal Hypertension	75%	70%
Ascites	55%	40%
Variceal Bleeding	30%	20%
Hepatocellular Carcinoma	35%	20%

Portal hypertension was observed in 75% of HBV patients with cirrhosis and 70% of HCV patients. Ascites was present in 55% of HBV patients compared to 40% of HCV patients. Variceal bleeding was more common in HBV-related cirrhosis (30%) than in HCV-related cirrhosis (20%). Hepatocellular carcinoma (HCC) occurred more frequently in HBV patients (35%) compared to HCV patients (20%).



Graph 1: Comparison of HBV and HCV Complications

The graph comparing complications in patients with chronic hepatitis B (HBV) and chronic hepatitis C (HCV) highlights key differences in the rates of portal hypertension, ascites, variceal bleeding, and hepatocellular carcinoma (HCC). Portal hypertension is prevalent in both groups, with 75% of HBV patients and 70% of HCV patients affected, indicating that both infections lead to significant disruption in liver blood flow. However, more noticeable differences are seen in other complications. Ascites is more common in HBV patients, with 55% affected compared to 40% of HCV patients. This suggests that HBV-related cirrhosis leads to a more severe build-up of fluid in the abdominal cavity, possibly reflecting faster liver decompensation in HBV patients. Variceal bleeding, another serious complication, occurs in 30% of HBV patients and 20% of HCV patients, further indicating that HBV-related cirrhosis is more

aggressive in terms of complications related to increased pressure in the veins around the liver. The most striking difference is seen in the development of hepatocellular carcinoma (HCC). The graph shows that 35% of HBV patients develop HCC, compared to 20% of HCV patients. This suggests that HBV is a stronger risk factor for liver cancer, possibly due to the persistent presence of viral DNA in liver cells, even in patients receiving antiviral therapy. HCV patients, particularly those treated with direct-acting antivirals (DAAs), show lower cancer rates, reflecting the curative potential of these therapies in preventing progression to HCC.

Table 3: Survival Rates at 10 Years

Group	Survival Rate (%)
HBV Patients (Overall)	70%
HCV Patients (Overall)	60%
HBV Patients (With Antiviral Therapy)	80%
HCV Patients (With DAAs)	85%

The overall 10-year survival rate was 70% for HBV patients and 60% for HCV patients. However, among patients who received antiviral therapy, survival improved significantly. For HBV patients treated with nucleos(t)ide analogues, the survival rate was 80%, while for HCV patients treated with DAAs, the survival rate reached 85%, reflecting the efficacy of DAAs in achieving SVR and preventing further liver damage.

Table 4: Impact of antiviral therapy on cirrhosis progression

Infection Type	Antiviral Therapy	Effect on cirrhosis progression
Hepatitis B (HBV)	Nucleos(t)ide Analogues	Slower progression, fewer decompensation events
Hepatitis C (HCV)	Direct-Acting Antivirals (DAAs)	75% fibrosis regression, no further liver complications

Antiviral therapy had a profound impact on the progression of cirrhosis. In HBV patients, those receiving nucleos(t)ide analogues showed slower fibrosis progression and lower rates of decompensation. For HCV patients, the introduction of DAAs significantly reduced cirrhosis progression, with 75% of DAA-treated patients showing regression of fibrosis and no further liver complications during the follow-up period.

Discussion

This comparative study highlights significant differences in the progression and outcomes of hepatic cirrhosis in patients with chronic hepatitis B (HBV) and hepatitis C (HCV) infections. The findings underscore the distinct mechanisms driving cirrhosis in these two viral infections, the variable impact of antiviral therapies, and the differing rates of complications such as hepatocellular carcinoma (HCC), ascites, and portal hypertension.

The data show that patients with HBV tend to develop cirrhosis earlier than those with HCV, with an average time to cirrhosis onset of 20 years in HBV compared to 25 years in HCV. This accelerated progression in HBV patients is likely driven by ongoing immune-mediated liver damage, even in patients with low-grade inflammation. Chronic HBV infection, particularly in those who remain untreated or experience frequent viral reactivations, is associated with a higher risk of fibrosis progression and earlier development of cirrhosis. Conversely, the slower progression seen in HCV patients may be attributed to the pattern of chronic inflammation and the cumulative damage caused by the virus over time. This finding highlights the importance of early and aggressive monitoring in HBV patients to prevent rapid fibrosis progression and liver damage.

In terms of cirrhosis-related complications, the results show that HBV patients are more likely to develop severe outcomes such as portal hypertension, ascites, and HCC. The 35% incidence of HCC in HBV-related cirrhosis aligns with previous studies indicating that HBV is a potent carcinogen, even in patients with controlled viral replication. The persistence of covalently closed circular DNA (cccDNA) in hepatocytes despite antiviral therapy may explain the increased risk of HCC in HBV patients, as viral persistence can promote oncogenic pathways. On the other hand, HCV patients demonstrated lower rates of HCC (20%) but experienced significant benefits from antiviral therapy, with direct-acting antivirals (DAAs) resulting in fibrosis regression in 75% of treated patients. This outcome emphasizes the curative potential of DAAs in reducing cirrhosis progression and associated complications in HCV patients.

Another critical finding of this study is the impact of antiviral therapy on long-term survival outcomes. Both nucleos(t)ide analogues for HBV and DAAs for HCV were associated with improved survival rates, particularly in patients who achieved sustained virologic suppression. For HBV patients, nucleos(t)ide analogues effectively reduced the risk of decompensated cirrhosis and complications, although the risk of HCC remained elevated due to the persistence of viral DNA within liver cells. In HCV patients, DAAs not only prevented cirrhosis progression but also led to fibrosis regression and prevented further liver damage in the majority of patients. The 85% survival rate in DAA-treated patients compared to 60% in untreated HCV patients underscores the transformative impact of these therapies on disease outcomes.

While both HBV and HCV lead to cirrhosis, the study underscores the different challenges faced by clinicians in managing these infections. For HBV, the focus remains on controlling viral replication and preventing liver damage, as eradication of the virus is rare even with long-term antiviral therapy. Monitoring for HCC remains essential in HBV patients, even in those who achieve viral suppression, given the persistent oncogenic risk. For HCV, the availability of curative therapies like DAAs has fundamentally changed the disease landscape, allowing for the complete eradication of the virus in most patients and a significant reduction in the risk of cirrhosis-related complications. However, the long latency period of HCV-related cirrhosis means that many patients are diagnosed at later stages of the disease, underscoring the need for early detection and treatment.

Overall, the study highlights the importance of tailored management strategies for chronic hepatitis B and C patients. In HBV, early and consistent antiviral therapy can slow fibrosis progression, but long-term monitoring for cirrhosis and HCC remains crucial. In contrast, HCV patients benefit greatly from DAA therapy, which offers the possibility of curing the infection and reversing fibrosis in many cases. These findings support the use of antiviral therapies as a cornerstone of cirrhosis prevention and management in both HBV and HCV, but also emphasize the need for ongoing

surveillance and individualized care based on the specific viral etiology.

In conclusion, while HBV and HCV both contribute to significant global morbidity and mortality due to cirrhosis, the pathways to cirrhosis, complications, and outcomes differ markedly between the two infections. The advent of antiviral therapies has dramatically improved prognosis in both patient populations, particularly in HCV patients with access to curative DAAs. Ongoing research into optimizing antiviral therapies, improving early detection of cirrhosis, and addressing the persistent risk of HCC in HBV patients will be critical to reducing the burden of liver disease globally.

Conclusion

This study provides a comprehensive comparison of hepatic cirrhosis progression and outcomes in patients with chronic hepatitis B (HBV) and hepatitis C (HCV) infections. The findings reveal significant differences in the timing of cirrhosis onset, the prevalence of complications, and the impact of antiviral therapies. HBV patients tend to develop cirrhosis earlier and are at a higher risk of complications such as portal hypertension, ascites, and hepatocellular carcinoma (HCC), even when treated with nucleos(t)ide analogues. In contrast, HCV-related cirrhosis generally progresses more slowly, with direct-acting antivirals (DAAs) offering substantial benefits, including fibrosis regression and improved long-term survival. Antiviral therapy has proven to be a critical factor in managing cirrhosis for both HBV and HCV patients. Nucleos(t)ide analogues effectively control HBV replication and slow disease progression, while DAAs offer a curative option for most HCV patients, drastically reducing the risk of cirrhosis and its complications. Despite these advancements, HBV patients remain at an elevated risk of HCC, necessitating ongoing monitoring. In conclusion, while both HBV and HCV lead to hepatic cirrhosis, the clinical course and management strategies differ significantly. Tailored therapeutic approaches and vigilant monitoring are essential to improving patient outcomes, particularly for those at risk of advanced cirrhosis and liver cancer. These findings underscore the need for continued research and optimization of treatment protocols to further reduce the burden of liver cirrhosis globally.

References

1. Asghar MS, Ahsan MN, Rasheed U, Hassan M, Jawed R, Abbas MB, *et al*. Severity of non-B and non-C hepatitis versus hepatitis B and C associated chronic liver disease: A retrospective, observational, comparative study. Cureus. 2020 Dec;12(12).
2. Sporea I, Şirli R, Deleanu A, Tudora A, Popescu A, Curescu M, *et al*. Liver stiffness measurements in patients with HBV vs HCV chronic hepatitis: a comparative study. World journal of gastroenterology: WJG. 2010 Oct 10;16(38):4832.
3. Wu SD, Wang JY, Li L. Staging of liver fibrosis in chronic hepatitis B patients with a composite predictive model: a comparative study. World journal of gastroenterology: WJG. 2010 Jan 1;16(4):501.
4. Nishida T, Kobashi H, Fujioka SI, Fujio K, Takaguchi K, Ikeda H, *et al*. A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis. Journal of Gastroenterology and Hepatology. 2008 May;23(5):794-803.
5. Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: A comparative analysis. Hepatology. 1992 Apr;15(4):572-577.
6. Tong MJ, Weiner JM, Ashcavai MW, Redeker AG, Comparini S, Vyas GN. A comparative study of hepatitis B viral markers in the family members of Asian and non-Asian patients with hepatitis B surface antigen-positive hepatocellular carcinoma and with chronic hepatitis B infection. Journal of Infectious Diseases. 1979 Oct 1;140(4):506-512.
7. Oliveira CP, Kappel CR, Siqueira ER, Lima VM, Stefano JT, Michalczuk MT, *et al*. Effects of hepatitis C virus on cardiovascular risk in infected patients: A comparative study. International Journal of Cardiology. 2013 Apr 5;164(2):221-226.
8. Murawaki Y, Ikuta Y, Nishimura Y, Koda M, Kawasaki H. Serum markers for connective tissue turnover in patients with chronic hepatitis B and chronic hepatitis C: A comparative analysis. Journal of Hepatology. 1995 Aug 1;23(2):145-152.
9. Arora A, Sharma P, Tyagi P, Singla V, Arora V, Bansal N, *et al*. Hepatitis B virus infection can cause hepatocellular carcinoma in less advanced liver cirrhosis: a comparative study of 142 patients from North India. Journal of Clinical and Experimental Hepatology. 2013 Dec 1;3(4):288-295.
10. Chu CW, Hwang SJ, Luo JC, Wang YJ, Lu RH, Lai CR, *et al*. Comparison of clinical, virologic and pathologic features in patients with acute hepatitis B and C. Journal of Gastroenterology and Hepatology. 2001 Feb;16(2):209-214.
11. Nwulia FO, Seaberg EC, Rinaldo CR, Badri S, Witt M, Thio CL. Comparative risk of liver-related mortality from chronic hepatitis B versus chronic hepatitis C virus infection. Clinical Infectious Diseases. 2012 Aug 15;55(4):507-513.
12. Okuda K, Nakashima T, Sakamoto K, Ikari T, Hidaka H, Kubo Y, *et al*. Hepatocellular carcinoma arising in noncirrhotic and highly cirrhotic livers: A comparative study of histopathology and frequency of hepatitis B markers. Cancer. 1982 Feb 1;49(3):450-455.